These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 28473667)

  • 1. Reactivating nuclear PTEN to treat CLL.
    Bernardi R; Ghia P
    Oncotarget; 2017 May; 8(22):35486-35487. PubMed ID: 28473667
    [No Abstract]   [Full Text] [Related]  

  • 2. Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL).
    Leupin N; Cenni B; Novak U; Hügli B; Graber HU; Tobler A; Fey MF
    Br J Haematol; 2003 Apr; 121(1):97-100. PubMed ID: 12670337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The distribution of TP53 gene polymorphisms in chronic lymphocytic leukemia patients, sufferers of Chornobyl nuclear power plant accident.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV
    Exp Oncol; 2016 Dec; 38(4):252-256. PubMed ID: 28230820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic lymphocytic leukemia: pathophysiology and current therapy].
    Takizawa J
    Rinsho Ketsueki; 2017; 58(5):471-479. PubMed ID: 28592762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN.
    Collaud S; Tischler V; Atanassoff A; Wiedl T; Komminoth P; Oehlschlegel C; Weder W; Soltermann A
    BMC Cancer; 2015 Feb; 15():74. PubMed ID: 25884169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
    Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
    Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
    Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S
    Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.
    Bailón E; Ugarte-Berzal E; Amigo-Jiménez I; Van den Steen P; Opdenakker G; García-Marco JA; García-Pardo A
    J Leukoc Biol; 2014 Aug; 96(2):185-99. PubMed ID: 25080557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of expression of PTEN with AKT phosphorylation level in leukemia cells].
    Zhang YY; Liu T; Meng WT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1109-13. PubMed ID: 21129241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene polymorphisms of p53-mediated apoptosis in chronic lymphocytic leukemia patients: features of distribution depending on radiation factor in anamnesis.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV
    Probl Radiac Med Radiobiol; 2014 Sep; 19():223-30. PubMed ID: 25536560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 codon 72 single nucleotide polymorphism in chronic lymphocytic leukemia.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martіna ZV
    Exp Oncol; 2014 Dec; 36(4):258-61. PubMed ID: 25537220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The occurrence of chronic lymphocytic leukemia after chronic phase of chronic myeloid leukemia: case report and literature review.
    Crişan AM; BădeliŢă SN; Jardan C; Vasilache ED; Dobrea CM; Gheorghe A; Tălmaci R; Arion CV; Bardaş A; Găman AM; Coriu D
    Rom J Morphol Embryol; 2015; 56(3):1145-51. PubMed ID: 26662151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia.
    Bilous N; Abramenko I; Saenko V; Chumak A; Dyagil I; Martina Z; Kryachok I
    Leuk Res; 2017 Jul; 58():1-8. PubMed ID: 28364582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells.
    Sánchez-Martínez D; Lanuza PM; Gómez N; Muntasell A; Cisneros E; Moraru M; Azaceta G; Anel A; Martínez-Lostao L; Villalba M; Palomera L; Vilches C; García Marco JA; Pardo J
    Front Immunol; 2016; 7():454. PubMed ID: 27833611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.